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Department of Pathology, The Aga Khan University Hospital, Nairobi, Kenya2
Received 9 September 2010/Returned for modification 24 October 2010/Accepted 21 November 2010

Carbapenem-hydrolyzing ␤-lactamases belonging to Ambler
classes A, B, and D have been reported worldwide among
Enterobacteriaceae (10, 14, 18). The most clinically significant
are KPC-type (Ambler class A), IMP and VIM types (class B),
and OXA-48 (class D), mostly identified in Klebsiella pneumoniae as a source of nosocomial outbreaks (14). Most of
those isolates are multidrug resistant.
Recently, a novel metallo-␤-lactamase (MBL) named
NDM-1 (New Delhi metallo-␤-lactamase) has been identified
from K. pneumoniae (strain 05-506) and Escherichia coli isolates recovered in Sweden from a patient previously hospitalized in India (19). An extensive survey performed in the
United Kingdom, India, and Pakistan identified NDM-1-producing K. pneumoniae, E. coli, Citrobacter freundii, Morganella
morganii, Providencia spp., and Enterobacter cloacae isolates
(9). The presence of NDM-1 producers in hospitalized patients
in the United Kingdom was related in many cases to previous
hospitalization in the Indian subcontinent (9), and similar observations have been made in France (12, 15) and the Sultanate of Oman (11). Spread of this novel carbapenemase gene is
considered a serious threat since the reservoir of NDM-1 producers is at least in part related to the Indian subcontinent,
which is inhabited by the second-largest population in the
world and where NDM-1 producers are reported also in community-acquired infections (9, 12).
Our study was initiated using an archival collection of bacterial isolates from the Aga Khan University Hospital, Nairobi,
Kenya, for the purpose of surveillance of antibacterial resistance mechanisms and infection control audits. Seven multidrug-resistant K. pneumoniae strains isolated over a 3-year
period (2007 to 2009) were selected, all showing an identical
pattern of resistance. Those isolates had been recovered
mostly from urine, from patients who were all receiving antibiotic treatments when the samples had been recovered (Table
1). However, those treatments were not targeted toward the

carbapenem-resistant K. pneumoniae isolates that were systematically considered non-strictly invasive (Table 1).
The MICs were determined by Etest (AB bioMérieux,
Solna, Sweden) on Mueller-Hinton agar plates and by liquid
microdilution assays at 37°C, and results of susceptibility testing were interpreted according to the CLSI guidelines (6). The
isolates were resistant to all ␤-lactams, including carbapenems
with MIC values of ⬎32 g/ml for imipenem, meropenem,
ertapenem, and doripenem. In addition, they were resistant to
aminoglycosides, fluoroquinolones, chloramphenicol, sulfonamides, fosfomycin, and nitrofurantoin, the MIC of rifampin
was ⬎32 g/ml, and the MICs of tigecycline and colistin measured by Etest were 0.5 and 0.5 g/ml, respectively.
Results from MBL detection performed by using Etest MBL
strips (AB bioMérieux) were positive. Thus, PCR assays were
carried out with a series of primers designed for the detection
of several class B ␤-lactamase genes, blaIMP, blaVIM (16), and
blaNDM-1 (primer NDM-Fm, 5⬘-GGTTTGGCGATCTGGTTT
TC-3⬘; and primer NDM-Rm, 5⬘-CGGAATGGCTCATCAC
GATC-3⬘). The isolates were positive for blaNDM-1, and sequencing of the PCR products revealed 100% identity with the
published sequence of the blaNDM-1 gene (19). Noteworthy, all
the patients from whom the NDM-1-producing isolates had
been recovered were Kenyans living in Kenya, but the history
of their travel or contact with Indian or British populations
could not be recovered. All these isolates were identified from
hospitalized patients, and pulsed-field gel electrophoresis
(PFGE) was performed as described previously (3) to evaluate
any clonal relationship. PFGE analysis showed an identical
pattern for all isolates (Fig. 1). The hospitalization wards from
which the infected patients were originating were located in
distinct locations inside the hospital, and no source or index
cases could be identified. Very interestingly, the PFGE pattern
of those Kenyan isolates was very similar to that of the first
reported NDM-1-producing K. pneumoniae strain 05-506 identified in Sweden from a patient hospitalized in India in 2008
(Fig. 1) (9). It was also very similar to that of K. pneumoniae
strain 601, recently identified in the Sultanate of Oman (Fig.
1), for which a link with India was evidenced (11). This result
indicates a clonal link between those isolates identified in
Nairobi and this Indian strain. That clonal link was further
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Seven carbapenem-resistant NDM-1-positive Klebsiella pneumoniae isolates were recovered from patients
hospitalized between 2007 and 2009 in different wards at a referral and tertiary care center in Nairobi. Most
of the isolates were obtained from urine. All isolates carried the blaNDM-1 carbapenemase gene previously
reported from India, Pakistan, and the United Kingdom. These isolates were clonally related and expressed
many other resistance determinants, including ␤-lactamases CTX-M-15, OXA-1, OXA-9, CMY-6, and aminoglycoside resistance methylase RmtC. This work corresponds to the first report of NDM-1 producers in Africa.
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TABLE 1. Clinical features of the studied K. pneumoniae isolates and patient characteristicsa
Isolate
no.

Sex of
patient

Age of
patient (yr)

Hospital
unit

1
2
3
4
5
6

F
M
M
F
F
M

58
72
42
76
65
56

Medical
ICU
Medical
Medical
Medical
ICU

7

F

26

Maternity

ward
ward
ward
ward

Treatment of patient

Amoxicillin-clavulanate
Imipenem ⫹ amikacin
Imipenem ⫹ ciprofloxacin
Ciprofloxacin
Meropenem ⫹ amikacin
Meropenem ⫹ amikacin ⫹
ciprofloxacin
High-dose ofloxacin

Total duration
of patient
hospitalization
(days)

Outcome of
patient

Source of
isolation

Date of first
isolation
(mo/day/yr)

4
2
8
6
11
11

Discharged
Diedb
Discharged
Discharged
Discharged
Discharged

Urine
Urine
Urine
Urine
Urethral pus

05/23/2007
12/24/2007
11/01/2008
12/16/2008
01/02/2009

7

Discharged

Urine

03/11/2009

a

F, female; M, male; ICU, intensive care unit.
b
Death not attributed to infection (patient had terminal-stage cancer).

FIG. 1. Pulsed-field gel electrophoresis patterns of the seven
NDM-1-producing K. pneumoniae isolates from Nairobi and the single
NDM-1-producing K. pneumoniae isolate from India. Lane 1, Kp1;
lane 2, Kp2; lane 3, Kp3; lane 4, Kp4; lane 5, Kp5; lane 6, Kp6; lane 7,
Kp7; lane 8, K. pneumoniae 05-506 (19); lane 9, K. pneumoniae 601
(11); lane 10, unrelated K. pneumoniae strain (included as a comparative strain).

identified the rmtC methylase gene conferring high-level resistance to all aminoglycosides in the Kenyan isolates.
Transferability of the blaNDM-1 gene was studied by conjugation experiments as described previously (17), with a selection based on ceftazidime (30 g/ml) and azide (100 g/ml),
using K. pneumoniae Kp7 as the donor strain and E. coli J53
(resistant to azide) as the recipient strain. One of the obtained
transconjugants, E. coli(pKp7-A) expressing NDM-1, had decreased susceptibility to carbapenems (MIC values of imipenem, meropenem, ertapenem, and doripenem were 4, 1.5,
1.5, and 1.5 g/ml, respectively [MICs for these same molecules were 0.12 g/ml for the E. coli J53 recipient strain]). It
was resistant to all aminoglycosides and to sulfonamides, and
PCR analysis confirmed that plasmid pKp7 coharbored the
rmtC gene. This plasmid, analyzed by using the Kieser technique (8), was 120 kb in size and belonged to the IncA/C2
incompatibility group as demonstrated by the PCR-based replicon typing method (2), whereas the blaNDM-1-positive plasmid in K. pneumoniae 05-506 was untypeable (9), and that of K.
pneumoniae 601 from the Sultanate of Oman was reported to
belong to the IncL/M group (11). Kumarasamy et al. (9) reported blaNDM-1-positive plasmids from the Indian isolates
that were either untypeable or belonged to the IncA/C or
IncFI/FII plasmid incompatibility group. Another type of
transconjugant was obtained, E. coli(pKp7-B), expressing an
ESBL phenotype. It harbored the blaCTX-M-15 and blaTEM-1
genes, had a 75-kb plasmid, belonged to the InF group, and did
not carry any other non-␤-lactam resistance markers.
PCR mapping was performed to identify the genetic sequences surrounding the blaNDM-1 gene in K. pneumoniae Kp7
for comparison with the sequences surrounding the blaNDM-1
gene in K. pneumoniae 05-506 (19). PCR experiments based on
primers located in those surrounding sequences produced negative results, indicating that the structures identified in K.
pneumoniae 05-506 were not present on plasmid pKp7.
Our study further underlines the spread of the blaNDM-1
gene worldwide, as exemplified by the newly reported NDM1-producing E. coli isolate identified in Australia (13), together
with the report of NDM-1-producing E. coli, K. pneumoniae,
and Enterobacter cloacae in the United States (5). This work is
the first to report the dissemination of that gene in Africa
which actually corresponds to the very first known identification of an NDM-1 producer. It has been traced to 2007, prior
to the first known identification of an NDM-1 producer in 2008
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confirmed by performing multilocus sequence typing as described previously (7) which showed that the K. pneumoniae
isolates of Kenya belonged to the ST14 sequence type, as
reported for K. pneumoniae 05-506 (19).
Since high-level resistance to cephalosporins and monobactam aztreonam (a substrate spared by NDM-1) was observed
for all isolates, detection of extended-spectrum ␤-lactamase
(ESBL) and AmpC productions was carried out by PCR analysis using specific primers to detect broad-spectrum ␤-lactamase genes (4), followed by sequencing. All isolates harbored
the blaSHV-28 and blaCTX-M-15 ESBL genes, together with the
blaCMY-6 AmpC gene and the blaOXA-1 and blaOXA-9 class D
␤-lactamase genes. Yong et al. (19) reported that the NDM1-positive K. pneumoniae strain 05-506 was blaCMY-4 positive.
Screening of 16S rRNA genes encoding methylase, performed
by using a multiplex PCR approach as described previously (1),
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in Sweden (19). Histories of contacts or the origin of the
Kenyan patients to the Indian subcontinent could not be evidenced. However, taking into account the size of the Indian
diaspora in Kenya (100,000 people), it remains possible that
introduction of NDM-1-producing K. pneumoniae in the Kenyan population could be linked to the Indian subcontinent. At
the same time it may be speculated that the large international
community traveling in and out of Kenya and the air traffic
between Europe, the United Kingdom, and East Africa could
have easily facilitated such an event. The clonal relationship
between the NDM-1-positive K. pneumoniae isolate 05-506
from Sweden, the K. pneumoniae isolate 601 from the Sultanate of Oman, and the Kenyan isolates presents a very strong
argument that this link might exist. Interestingly, K. pneumoniae isolates belonging to the same clonal lineage were
found to harbor different blaNDM-1-positive plasmids. This is in
accordance with the observations made by Kumarasamy et al.
(9), who showed an important diversity of plasmid size and
scaffolds among NDM-1-positive isolates recovered from the
United Kingdom, India, and Pakistan.
Finally, this report described the first occurrence of NDM-1
producers in Africa. However, this may not be considered a
nosocomial outbreak since these isolates were recovered over
a long period of time and from patients who did not have any
obvious epidemiological connection. The multidrug resistance
pattern of the K. pneumoniae isolates identified here mirrors
that of NDM-1 producers previously identified in India, Pakistan, and the United Kingdom and is a source of deep concern.
As extensively reported for outbreaks of ESBL producers, K.
pneumoniae is a bacterial species that is prone to being an
excellent vector for hospital dissemination of resistance genes.
We fear that gene exchanges similar to those observed extensively for ESBL genes may occur for the blaNDM-1 gene, i.e.,
gene circulation in community-acquired E. coli which is then
transferred to hospital-based K. pneumoniae.
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